Stock EYPT EYEPOINT PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News EyePoint Pharmaceuticals, Inc.

Equities

EYPT

US30233G2093

Market Closed - Nasdaq
Other stock markets
 21:00:00 25/06/2024 BST 		5-day change 1st Jan Change
8.26 USD -3.05% Intraday chart for EyePoint Pharmaceuticals, Inc. -4.95% -64.26%
06-12 Transcript : EyePoint Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 03:20 PM
06-04 JPMorgan Adjusts EyePoint Pharmaceuticals Price Target to $32 From $35, Maintains Overweight Rating MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
EyePoint Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(4)
AQ
EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024
AQ
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
AQ
Transcript : EyePoint Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 03:20 PM
EyePoint Pharmaceuticals : Goldman Sachs Global Healthcare Conference Presentation
PU
EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
AQ
JPMorgan Adjusts EyePoint Pharmaceuticals Price Target to $32 From $35, Maintains Overweight Rating
MT
EyePoint Pharmaceuticals : Investor Presentation May 2024
PU
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
AQ
Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating
MT
Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q1 Revenue $11.7M
MT
EyePoint Pharmaceuticals: Q1 Earnings Snapshot
AQ
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments
AQ
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Chardan Research Adjusts EyePoint Pharmaceuticals' PT to $28 From $39 After Data From PAVIA Study of Duravyu Disappoint; Keeps Buy Rating
MT
Mizuho Securities Cuts Price Target on EyePoint Pharmaceuticals to $30 From $39, Maintains Buy Rating
MT
EyePoint Pharmaceuticals : PAVIA Topline Data Conference Call Presentation
PU
Sector Update: Health Care Stocks Gain Pre-Bell Monday
MT
EyePoint Pharmaceuticals Shares Fall After Diabetes Drug Fails to Meet Primary Endpoint
MT
EyePoint Pharmaceuticals Shares Slide 32% on Duravyu Trial Missing Primary Endpoint
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EYPT Stock
  4. News EyePoint Pharmaceuticals, Inc.